Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program

Journal of Substance Abuse Treatment

Volumn 75, Issue , 2017, Pages 49-53

  Butner, Jenna L ^a,b   Gupta, Neil ^a   Fabian, Chris ^b   Henry, Susan ^b   Shi, Julia M ^a,b   Tetrault, Jeanette M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b APT Foundation ^*  (United States)

Author keywords

Direct acting antivirals (DAA); Hepatitis C (HCV); Opioid treatment program (OTP); People who inject drugs (PWID); Substance use disorder (SUD)

Indexed keywords

ANTIVIRUS AGENT; BUPRENORPHINE; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; METHADONE; OMBITASVIR; OPIATE; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SOFOSBUVIR;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DEPENDENCE TREATMENT; FEMALE; FOLLOW UP; HEALTH EDUCATION; HEALTH PROGRAM; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICATION COMPLIANCE; NONHUMAN; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; COMPLICATION; CONNECTICUT; HARM REDUCTION; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PROCEDURES; SUBSTANCE ABUSE;

ADULT; ANTIVIRAL AGENTS; CONNECTICUT; FEMALE; HARM REDUCTION; HEPATITIS C; HUMANS; MALE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 85012255109     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2016.12.014     Document Type: Article

References (27)

1. Aaron, S., McMahon, J.M., Milano, D., Torres, L., Clatts, M., Tortu, S.,.. Simm, M., Intranasal transmission of hepatitis C virus: Virological and clinical evidence. Clinical Infectious Diseases 47:7 (2008), 931–934, 10.1086/591699.
2. AASLD, HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Retrieved from http://hcvguidelines.org/, 2016.
3. Ara, A.K., Paul, J.P., New direct-acting antiviral therapies for treatment of chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y) 11:7 (2015), 458–466.
4. State Medicaid Coverage Policies for Harvoni and Viekira Pak Treatment of Hepatitis C, (2015).
5. Dore, G., A., F., Litwin, A.H., et al. C-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy. 2015.
6. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O.,.. Group, C. E. C.-S. S, Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial. Annals of Internal Medicine, 2016, 10.7326/M16-0816.
7. Doyle, J.S., Aspinall, E.J., Hutchinson, S.J., Quinn, B., Gore, C., Wiktor, S.Z., Hellard, M.E., Global policy and access to new hepatitis C therapies for people who inject drugs. The International Journal on Drug Policy 26:11 (2015), 1064–1071, 10.1016/j.drugpo.2015.05.008.
8. Grebely, J., Oser, M., Taylor, L.E., Dore, G.J., Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels. The Journal of Infectious Diseases 207:Suppl. 1 (2013), S19–S25, 10.1093/infdis/jis928.
9. Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J.,.. International Network for Hepatitis in Substance, U, Recommendations for the management of hepatitis C virus infection among people who inject drugs. The International Journal on Drug Policy 26:10 (2015), 1028–1038, 10.1016/j.drugpo.2015.07.005.
10. Hajarizadeh, B., Grebely, J., Dore, G.J., Epidemiology and natural history of HCV infection. Nature Reviews. Gastroenterology & Hepatology 10:9 (2013), 553–562, 10.1038/nrgastro.2013.107.
11. Harris, K.A. Jr., Arnsten, J.H., Litwin, A.H., Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. Journal of Addiction Medicine 4:1 (2010), 20–26, 10.1097/ADM.0b013e3181add3de.
12. Lalezari, J., Sullivan, J.G., Varunok, P., Galen, E., Kowdley, K.V., Rustgi, V.,.. Cohen, D.E., Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology 63:2 (2015), 364–369, 10.1016/j.jhep.2015.03.029.
13. Litwin, A.H., Harris, K.A. Jr., Nahvi, S., Zamor, P.J., Soloway, I.J., Tenore, P.L.,.. Arnsten, J.H., Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 37:1 (2009), 32–40, 10.1016/j.jsat.2008.09.009.
14. Marinho, R.T., Costa, A., Pires, T., Raposo, H., Vasconcelos, C., Polonia, C.,.. Investigators, L.-C., A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. BMC Infectious Diseases, 16(1), 2016, 565, 10.1186/s12879-016-1883-6.
15. Martinez, A., Talal, A.H., Noninjection drug use: An under-appreciated risk factor for hepatitis C virus transmission. Liver International 28:6 (2008), 757–760, 10.1111/j.1478-3231.2008.01765.x.
16. Mehta, S.H., Genberg, B.L., Astemborski, J., Kavasery, R., Kirk, G.D., Vlahov, D.,.. Thomas, D.L., Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health 33:3 (2008), 126–133, 10.1007/s10900-007-9083-3.
17. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C, Hepatology 26:3 Suppl 1 (1997), 2S–10S, 10.1002/hep.510260701.
18. Neff, G.W., D., C., Schiff, E.R., The current economic burden of cirrhosis. Gastroenterology & Hepatology 7:10 (2011), 661–671.
19. Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., Gitlin, N.,.. Team, A.-S., All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61:4 (2015), 1127–1135, 10.1002/hep.27726.
20. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., Degenhardt, L., Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 378:9791 (2011), 571–583, 10.1016/S0140-6736(11)61097-0.
21. Oramasionwu, C.U., Moore, H.N., Toliver, J.C., Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: A review. AIDS Patient Care and STDs 28:5 (2014), 228–239, 10.1089/apc.2014.0033.
22. Stein, M.R., Soloway, I.J., Jefferson, K.S., Roose, R.J., Arnsten, J.H., Litwin, A.H., Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. Journal of Substance Abuse Treatment 43:4 (2012), 424–432, 10.1016/j.jsat.2012.08.007.
23. Thursz, M., Fontanet, A., HCV transmission in industrialized countries and resource-constrained areas. Nature Reviews. Gastroenterology & Hepatology 11:1 (2014), 28–35, 10.1038/nrgastro.2013.179.
24. Walley, A.Y., White, M.C., Kushel, M.B., Song, Y.S., Tulsky, J.P., Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment 28:2 (2005), 181–187, 10.1016/j.jsat.2004.12.004.
25. Wolfe, D., Luhmann, N., Harris, M., Momenghalibaf, A., Albers, E., Byrne, J., Swan, T., Human rights and access to hepatitis C treatment for people who inject drugs. The International Journal on Drug Policy 26:11 (2015), 1072–1080, 10.1016/j.drugpo.2015.05.007.
26. Woodrell, C., Weiss, J., Branch, A., Gardenier, D., Krauskopf, K., Kil, N.,.. Sigel, K., Primary care-based hepatitis C treatment outcomes with first-generation direct-acting agents. Journal of Addiction Medicine 9:5 (2015), 405–410, 10.1097/ADM.0000000000000147.
27. Zuccaro, V., Columpsi, P., Apollinari, A., Sacchi, P., Mussa, M., Schimmenti, A.,.. Bruno, R., Emerging biological agents for hepatitis C. Expert Opinion on Emerging Drugs 21:2 (2016), 219–224, 10.1080/14728214.2016.1184645.